Research across Metabolic Dysfunction-Associated Steatohepatitis
Related studies from across the Metabolic Dysfunction-Associated Steatohepatitis family.
MicroRNAs influence lipid metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis progression
Small molecules called microRNAs may help track and treat liver disease
This systematic review examines the role of microRNAs (miRNAs) in the pathophysiology of nonalcoholic fatty liver disease. The authors synth…
New research highlights how tiny molecules called microRNAs influence liver inflammation and scarring, offering hope for better diagnosis an…
Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patients
Semaglutide helps resolve liver inflammation in patients with MASH
This meta-analysis of 1908 patients with MASLD and MASH found that semaglutide significantly improved MASH resolution (OR 3.48) and reduced …
New data shows semaglutide can reduce liver fat and inflammation for people with fatty liver disease, though results on scarring vary.
Proposed pathway for systematic MASLD/MASH assessment in type 2 diabetes
New Pathway Proposed to Manage Liver Disease in Diabetes Patients
This narrative review proposes a structured, risk-adapted outpatient pathway for MASLD/MASH assessment in patients with type 2 diabetes, sta…
A new proposed management plan aims to help people with type 2 diabetes identify and assess liver conditions more systematically.
Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progression
Semaglutide shows promise for treating fatty liver disease and NASH
This meta-analysis of randomized controlled trials evaluated subcutaneous semaglutide in adults with NAFLD or NASH. The analysis found signi…
A new analysis shows that semaglutide can help resolve liver inflammation and improve metabolic health in people with fatty liver disease.
Immune crosstalk between innate and adaptive compartments drives inflammatory mechanisms in MASLD and MASH progression
Immune system crosstalk drives fatty liver disease progression
This systematic review examines the role of immune system interactions in metabolic dysfunction-associated steatotic liver disease (MASLD) a…
A new review reveals that immune cells talking to each other may be what pushes fatty liver disease toward severe liver damage.
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Narrative review explores immunometabolic networks in MASH and MASLD
Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…
Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk
New meta-analysis shows how many patients improve on placebo for MASH
This systematic review and meta-analysis examined placebo outcomes in patients with metabolic dysfunction-associated steatohepatitis.
This analysis of 6,880 patients reveals natural improvement rates in metabolic dysfunction-associated steatohepatitis when no active drug is…
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…